Anaptysbio, Inc ANAB
We take great care to ensure that the data presented and summarized in this overview for ANAPTYSBIO, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ANAB
Top Purchases
Top Sells
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Insider Transactions at ANAB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2025
|
J. Anthony Ware |
SELL
Open market or private sale
|
Direct |
3,900
-28.82%
|
$191,100
$49.58 P/Share
|
|
Dec 23
2025
|
John P. Schmid |
SELL
Other acquisition or disposition
|
Indirect |
11,068
-100.0%
|
$564,468
$51.0 P/Share
|
|
Dec 22
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-52.78%
|
$510,000
$51.0 P/Share
|
|
Dec 22
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.55%
|
$140,000
$14.02 P/Share
|
|
Dec 22
2025
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-51.54%
|
$500,000
$50.0 P/Share
|
|
Dec 22
2025
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.01%
|
$200,000
$20.16 P/Share
|
|
Dec 22
2025
|
Paul F. Lizzul Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,500
-5.27%
|
$75,000
$50.0 P/Share
|
|
Dec 22
2025
|
Paul F. Lizzul Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+5.01%
|
$27,000
$18.5 P/Share
|
|
Dec 18
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
141
-1.55%
|
$6,486
$46.99 P/Share
|
|
Dec 17
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-52.39%
|
$460,000
$46.0 P/Share
|
|
Dec 17
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+34.38%
|
$140,000
$14.02 P/Share
|
|
Dec 16
2025
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,725
-38.81%
|
$691,900
$44.91 P/Share
|
|
Dec 16
2025
|
Dennis Mulroy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+28.47%
|
$200,000
$20.16 P/Share
|
|
Dec 16
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
12,500
-35.03%
|
$550,000
$44.96 P/Share
|
|
Dec 16
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+25.99%
|
$212,500
$17.09 P/Share
|
|
Sep 30
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,240
-47.55%
|
$238,960
$29.0 P/Share
|
|
Sep 30
2025
|
Eric J Loumeau CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+22.39%
|
$70,000
$14.02 P/Share
|
|
Sep 15
2025
|
John A Orwin |
BUY
Exercise of conversion of derivative security
|
Direct |
1,300
+10.87%
|
-
|
|
Aug 08
2025
|
Hollings Renton |
SELL
Open market or private sale
|
Direct |
10,231
-39.69%
|
$194,389
$19.57 P/Share
|
|
Aug 08
2025
|
Hollings Renton |
BUY
Exercise of conversion of derivative security
|
Direct |
10,231
+40.24%
|
$61,386
$6.93 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 19.9K shares |
|---|---|
| Exercise of conversion of derivative security | 273K shares |
| Other acquisition or disposition | 11.1K shares |
| Payment of exercise price or tax liability | 36.7K shares |
|---|---|
| Open market or private sale | 109K shares |
| Other acquisition or disposition | 11.1K shares |